FLK-1 is a receptor for vascular endothelial growth factor
Patent 5851999 Issued on December 22, 1998. Estimated Expiration Date: 
December 22, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
December 22, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorsAssignee
ApplicationNo. 443861 filed on 05/22/1995US Classes:514/44, Polynucleotide (e.g., RNA, DNA, etc.)424/93.2, Genetically modified micro-organism, cell, or virus (e.g., transformed, fused, hybrid, etc.)435/320.1VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)ExaminersPrimary: Campell, Bruce R.Attorney, Agent or FirmInternational ClassesA61K 048/00C12N 005/00 C12N 015/00 AbstractThe present invention relates to the use of ligands for the FLK-1 receptor for the modulation of angiogenesis and vasculogenesis. The invention is based, in part, on the demonstration that Flk-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of Flk-1. These results indicate a major role for Flk-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express Flk-1 and the uses of expressed Flk-1 to evaluate and screen for drugs and analogs of VEGF involved in Flk-1 modulation by either agonist or antagonist activities is described. The invention also relates to the use of FLK-1 ligands, including VEGF agonists and antagonists, in the treatment of disorders, including cancer, by modulating vasculogenesis and angiogenesis.Other References
Field of SearchPolynucleotide (e.g., RNA, DNA, etc.)Recombinant DNA technique included in method of making a protein or polypeptide VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.) Expressing recombinant receptor Method of regulating cell metabolism or physiology Genetically modified micro-organism, cell, or virus (e.g., transformed, fused, hybrid, etc.) |
| ||||||||||||||
